Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023
For the year, the company expects net product sales from continuing operations to be approximately $128 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.26 USD | -2.41% | -8.04% | -41.49% |
1st Jan change | Capi. | |
---|---|---|
-41.49% | 400M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |